Ascletis Reports ASC30 Half-Life of 36 Days, Enabling Once‑Monthly Dosing
September 9, 2025
Ascletis Pharma Inc. has shared preliminary results from its U.S. Phase Ib study testing ASC30, a long-lasting small molecule GLP-1 receptor agonist. The subcutaneous version
